12 month risk of opioid overdose in patients with T2DM and OUD
(Comparision between matched semaglutide vs other anti−diabetes medications groups)

Size/group	Exposure group	Comparison group	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)		HR (95% CI)
2,568	semaglutide	insulins	40 (1.6%)	78 (3.0%)		0.50 (0.34−0.73)
2,427	semaglutide	metformin	38 (1.6%)	82 (3.4%)		0.46 (0.32−0.68)
1,652	semaglutide	DPP−4i	28 (1.7%)	52 (3.1%)		0.53 (0.34−0.84)
2,167	semaglutide	SGLT2i	32 (1.5%)	51 (2.4%)		0.61 (0.40−0.96)
1,984	semaglutide	SU	29 (1.5%)	56 (2.8%)		0.52 (0.33−0.81)
724	semaglutide	TZD	13 (1.8%)	16 (2.2%)		0.80 (0.38−1.67)
2,128	semaglutide	other GLP−1RAs	31 (1.5%)	54 (2.5%)		0.58 (0.37−0.90)

Hazard Ratio (HR)

0.20 0.30 0.50 0.80 2.0 3.00 5.00